Phase I
A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV1521 in Participants With Advanced Solid Tumors
- Study HIC#:2000037357
- Last Updated:09/06/2024
This study is testing a new medicine, SNV1521, for people with advanced cancers. The researchers want to find out if SNV1521 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the most effective and safe one.
Contact Us
For more information about this study, including how to volunteer, contact:
Ingrid Palma
- Phone Number: 1-203-785-6431
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
Eligibility Criteria
Inclusion Criteria:
- Advanced or metastatic solid tumor malignancy
- Refractory to or intolerant of available therapies
- Evaluable or Measurable disease (RECIST 1.1 Criteria).
- ECOG Performance Status 0 or 1.
- Life expectancy > 3 months
Exclusion Criteria:
- Active brain metastasis or carcinomatous meningitis
- History of other malignancy within the past 2 years
- Significant cardiovascular disease within 6 months
- Significant gastrointestinal disease
- HIV infection with a CD4+ T-cell count < 200 cells/μL and/or a detectable viral load
- Liver dysfunction
